Oct 2026· Oncology, Nuclear Medicine and Transplantology· Vol 2, pp. onmt029· 0 citations· 33 references
TL;DR
This review critically examines whether longitudinal liquid-biopsy measurement, combined with artificial intelligence (AI), can move oncology from tumour monitoring toward genuine prediction of cancer evolution and treatment resistance.
Abstract
Cancer behaves as a dynamic evolutionary system, whereas conventional tissue biopsy and imaging provide incomplete temporal information about how a tumour is changing. This review critically examines whether longitudinal liquid-biopsy measurement, combined with artificial intelligence (AI), can move oncology from tumour monitoring toward genuine prediction of cancer evolution and treatment resistance. We synthesise mechanistic, clinical, and computational evidence on circulating tumour DNA, circulating tumour cells, extracellular vesicles, and multimodal liquid-biopsy platforms, together with AI approaches applied to longitudinal cancer data, drawing on landmark and recent studies across colorectal, lung, breast, and ovarian cancer. Current evidence distinguishes three increasingly demanding tasks: early detection, longitudinal monitoring, and genuine forecasting. Longitudinal circulating tumour DNA analysis can detect molecular progression and emerging resistance mutations months before radiographic progression, and machine-learning models can stratify survival using serial biomarker metrics; however, most published "AI prediction" studies demonstrate earlier detection or prognostic association rather than prospectively validated forecasting of a future, patient-specific event. Biological variability in tumour shedding, analytical noise, small and irregularly sampled longitudinal datasets, overfitting, data leakage, weak external validation, and limited interpretability constrain the transition from detection to actionable prediction. AI-enabled liquid biopsy has genuine potential to forecast tumour trajectories, but current evidence is considerably stronger for molecular monitoring and early detection than for prospectively validated, clinically actionable prediction. Realising this potential will require standardised assays, prospective longitudinal cohorts with predefined prediction horizons, rigorous external and temporal validation, calibrated and interpretable models, and interventional trials linking predictions to treatment decisions before AI-enabled liquid biopsy can be considered ready to guide clinical care.
Current evidence indicates that AI can extract complementary biological information from complex circulating biomarker datasets, but prospective validation is still required before widespread implementation, and this review addresses major translational barriers.
Vanessa Gąsiorowska, Karolina Grodkowska-Szukała, Ewa Jachimczak et al.· International Journal of Inn...· 0 citations
Triple-negative breast cancer (TNBC) is a biologically heterogeneous and clinically aggressive breast cancer subtype in which therapeutic resistance often emerges despite initial chemosensitivity. Conventional tissue biomarkers remain essential for diagnosis and initial treatment selection, but they provide limited inf...
Chinni Krishna Khandavalli, Jagannadham Nuthana Yashwanth, E. Balakoti et al.· Biosciences Biotechnology Re...· 0 citations
The biological processes that influence ctDNA release, fragmentation, and clearance, including tumor cell turnover and cell death pathways, are discussed, as these directly affect its abundance in blood.
PURPOSE OF REVIEW
Circulating tumor DNA (ctDNA) is increasingly used for molecular profiling in breast cancer, and its role as a longitudinal biomarker is expanding. This review examines recent evidence on serial ctDNA assessment, focusing on minimal residual disease (MRD) and molecular relapse in early breast cancer (...
G. R. Oliva, M. Cristofanilli, C. Reduzzi et al.· Current Opinion in Obstetric...· 0 citations
Circulating tumour DNA (ctDNA) represents an emerging liquid biopsy tool with significant clinical utility in gastric cancer detection, monitoring and prognostication. Multicancer early detection blood tests achieve 66.7% sensitivity for advanced disease and up to 81% for early-stage detection using methylation-based a...
A. Naz, Leon Tom Peter, Wojciech Blonski et al.· Considerations in Medicine· 0 citations
Colorectal cancer (CRC) remains one of the most common malignancies worldwide and a leading cause of cancer-related mortality. Recent advances in CRC molecular biology have focused on biomarkers for early detection, prognostic stratification, treatment selection, and disease monitoring. Clinically validated biomarkers,...
Katarzyna Herbetko, Aleksandra Herbetko, Sara Suwała et al.· Cells· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.